Samaritan is the Little Biotech That Could Be Remembered for Alzheimer's

Samaritan Pharmaceuticals Inc. (AMEX:LIV):

   --  Alzheimer's Expected to Claim 14M Lives by 2050

   --  Analyst Predict Alzheimer's Market Could Reach $4B Annually by
        2013

   Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of
innovative drugs, announced today, its Alzheimer's drug SP233,
recently registered as Caprospinol, showed no toxic effects in
standard preclinical assays used to evaluate its safety. This is an
important finding for SP233's future as a possible life-saving,
memory-saving, Alzheimer's drug. Samaritan has concluded a number of
preclinical studies of SP233, in preparation to file an
investigational new drug (IND) application, with the FDA.
   While the jury is still out as to the exact cause of Alzheimer's,
most researchers think a buildup of the protein beta-amyloid in the
brain is what causes the disease. So far, each preclinical study has
given Samaritan hope that SP233 holds promise to exert neuroprotective
properties against beta-amyloid toxicity.
   Dr. Greeson, CEO of Samaritan stated, "We are wrapping up the last
preclinical study to file an IND with the FDA, it's been a complex
process but we are almost there, it's exciting. We are cautiously
optimistic the FDA will grant us an IND and if so, SP233 would be one
of the few drugs to be tested in humans that could actually treat
Alzheimer's, not just alleviate its symptoms."

   Samaritan Pharmaceuticals: "We LIV....to Save Lives."

   Samaritan is a small-cap Biotech, driven to discover, develop, and
commercialize, innovative therapeutics' for AIDS, Alzheimer's, Cancer
and Heart disease. Look at www.samaritanpharma.com. Please register on
Website so we can notify you of upcoming conference calls, news and
events.

   Disclaimer

   The company disclaims any information that is created by an
outside party and endorses only information that is communicated by
its press releases, filings and Website. This news release contains
forward-looking statements that reflect management's current beliefs
about the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and
regulatory review. There are no guarantees that products will prove to
be commercially successful. For additional information about the
factors that affect the company's business, please read the company's
latest Form 10-K filed April 15, 2005. The company undertakes no duty
to update forward-looking statements.